FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma

[FDA]

On August 9, 2023, the Food and Drug Administration granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.)


Baca selengkapnya di : http://www.fda.gov...